• About
  • Policies
  • What is open access
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • University Library
      • Bilkent Theses
      • Theses - Department of Molecular Biology and Genetics
      • Dept. of Molecular Biology and Genetics - Master's degree
      • View Item
      •   BUIR Home
      • University Library
      • Bilkent Theses
      • Theses - Department of Molecular Biology and Genetics
      • Dept. of Molecular Biology and Genetics - Master's degree
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      miRNA-mRNA interaction network regulating chemotherapy resistance in triple negative breast cancer

      Thumbnail
      Embargo Lift Date: 2020-01-15
      View / Download
      4.9 Mb
      Author(s)
      Assidicky, Ridho
      Advisor
      Şahin, Özgür
      Date
      2019-06
      Publisher
      Bilkent University
      Language
      English
      Type
      Thesis
      Item Usage Stats
      217
      views
      195
      downloads
      Abstract
      Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking the expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2). Compared to other subtypes, which can be treated with targeted therapies, chemotherapy is the major regimen used to treat TNBCs. Moreover, TNBC patients have better response rate to chemotherapy compared to other breast cancer (BC) subtypes. However, patients develop resistance rapidly, which in turn significantly increases the mortality rate. Therefore, there is urgent unmet need for elucidating the mechanisms of chemotherapy resistance in TNBC and identifying novel targets that can overcome resistance or potentiate the efficacy of chemotherapy. In this line, we developed an in vivo chemoresistant TNBC xenograft model, performed whole transcriptome sequencing of these tumors, and built a miRNA-mRNA interaction network regulating TNBC chemoresistance. We identified an ECM glycoprotein (“EG”) as the central chemoresistance driver gene, and a candidate potential tumor suppressor miRNA (“TSM”) sensitizing cells to EG-induced chemoresistance. Mechanistically, TSM was downregulated by hypoxia in chemoresistant tumor microenvironment that, in turn, led to upregulation of an integrin family protein (“IFP”), which encodes a subunit of receptor recognizing EG. We further showed that TSM directly binds the 3’-UTR of IFP, represses its expression, and inhibits FAK/Src signaling, PI3K signaling and MAPK signaling pathways, which constitute the major pathways in cell survival. Importantly, overexpression of TSM or inhibition of the IFP overcame EG-driven chemotherapy resistance in vitro and potentiated the efficacy of chemotherapy in vivo. Overall, we built the first miRNA-mRNA interaction network of TNBC chemoresistance and identified a hypoxia-regulated novel tumor suppressor miRNA, TSM, or its target IFP as potential targets overcoming chemoresistance or potentiating the efficacy of chemotherapy in TNBCs.
      Keywords
      TNBC
      Chemotherapy
      Chemoresistance
      ECM glycoprotein (EG)
      Tumor suppressor miRNA (TSM)
      Integrin family protein (IFP)
      Hypoxia
      Integrin signaling
      Chemosensitization
      Permalink
      http://hdl.handle.net/11693/52306
      Collections
      • Dept. of Molecular Biology and Genetics - Master's degree 148
      Show full item record

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCoursesThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCourses

      My Account

      Login

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 2976
      © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy